Market Cap: $3.4B
AI
Acadia Pharmaceuticals Inc.
ACAD
NASDAQ (NASDAQ Global Select)USD
Market Cap: $3.4B
Acadia Pharmaceuticals makes significant strides in the treatment landscape for Rett syndrome with a recent recommendation from the European Medicines Agency (EMA). Following the EMA’s Committee for M…
Acadia Pharmaceuticals announces the upcoming retirement of Dr. Elizabeth H.Z. Thompson, the current Head of Research and Development. Dr. Thompson will transition out of her role while continuing her…
Acadia Pharmaceuticals announces the rollout of DAYBUE STIX, a cutting-edge powder formulation of trofinetide for patients with Rett syndrome. This launch follows FDA approval granted in December 2025…
Acadia Pharmaceuticals announces the launch of DAYBUE STIX, a new powder formulation of trofinetide, tailored for patients aged two and older with Rett syndrome. This announcement comes on the heels o…
I apologize, but without the specific content to summarize, I cannot generate an article. Please provide the text or key information related to Acadia Pharmaceuticals or any relevant developments, and…
### Acadia Pharmaceuticals Advances Innovation in Neurological Treatments Acadia Pharmaceuticals is making significant strides in the development of innovative treatments for neurological disorders. T…
Acadia Pharmaceuticals Navigates Diverse Analyst Opinions Amid Market Uncertainty In recent months, Acadia Pharmaceuticals (NASDAQ: ACAD) finds itself at the center of a complex analytical landscape,…
Acadia Pharmaceuticals: Pioneering Innovation in Neurology Amidst Economic Challenges Acadia Pharmaceuticals focuses on developing innovative treatments for neurological conditions, particularly Parki…
Acadia Pharmaceuticals Prepares for Earnings Report Amid Industry Optimism Acadia Pharmaceuticals, a leader in the development of innovative therapies for neurological and psychiatric disorders, is po…
Acadia Pharmaceuticals: Strategic Focus on Market Expansion and Innovation Acadia Pharmaceuticals gears up for a pivotal moment as it continues to enhance its market presence and commitment to innovat…
Avant Technologies Pioneers Cell-Based Therapeutics Amid Regulatory Evolution Avant Technologies Inc. is making significant strides in the biopharmaceutical landscape by shifting towards a partnership…
Avant Technologies: Pioneering Cell-Based Therapeutics Amid Regulatory Shifts Avant Technologies Inc. is strategically pivoting towards a partnership-driven model in the realm of biotechnological inno…
Acadia Pharmaceuticals Embraces the Shift Towards Cell-Based Therapies Acadia Pharmaceuticals finds itself in a rapidly transforming biopharmaceutical landscape, where the focus is shifting from tradi…
Analysts Weigh In on ACADIA Pharmaceuticals: A Mixed Bag of Insights In the past three months, ACADIA Pharmaceuticals finds itself at the center of heightened analyst scrutiny, as 11 financial analyst…
Acadia Pharmaceuticals Faces Divergent Analyst Opinions Amid Research Initiatives In recent months, ACADIA Pharmaceuticals experiences heightened scrutiny from financial analysts, with 11 experts weig…
Acadia Pharmaceuticals Advances Treatment for Prader-Willi Syndrome with Promising Trial Results Acadia Pharmaceuticals Inc. takes a significant step forward in addressing a critical health concern fo…
Acadia Pharmaceuticals Advances in Treatment for Prader-Willi Syndrome Acadia Pharmaceuticals Inc. announces promising topline results from its Phase 3 COMPASS PWS trial, focusing on the efficacy and…
Acadia Pharmaceuticals Advances Treatment for Prader-Willi Syndrome with Phase 3 Trial Results Acadia Pharmaceuticals Inc. announces promising topline results from its Phase 3 COMPASS trial, focusing…
Insider Selling at Acadia Pharmaceuticals: Implications for Leadership Confidence Mark Schneyer, the Executive Vice President of Acadia Pharmaceuticals, recently executed an insider sell on September…
Navigating Insider Trading and Corporate Governance at ACADIA Pharmaceuticals ACADIA Pharmaceuticals finds itself at a critical junction in the biopharmaceutical landscape, particularly as it develops…
Navigating Executive Movements: A Glimpse into ACADIA Pharmaceuticals' Leadership Decisions ACADIA Pharmaceuticals, a company dedicated to innovating treatments for neurological disorders, is currentl…
Acadia Pharmaceuticals: Navigating Analyst Perspectives on Future Growth In recent months, Acadia Pharmaceuticals finds itself at the center of diverse analyst opinions, as 12 financial experts weigh…
Acadia Pharmaceuticals: Navigating the Complex Landscape of Analyst Ratings In recent months, Acadia Pharmaceuticals faces a nuanced landscape of analyst ratings that encapsulate a wide range of persp…
Acadia Pharmaceuticals: Navigating Analyst Perspectives Amidst a Competitive Landscape In the evolving landscape of the pharmaceutical industry, ACADIA Pharmaceuticals finds itself under the scrutiny…
Acadia Pharmaceuticals Focuses on Advancing Neurological Treatments Amidst Market Dynamics Acadia Pharmaceuticals, a leader in the development of therapies for neurological disorders, continues to pus…